Endocyte Stock Price, News & Analysis (NASDAQ:ECYT)

$4.41 -0.20 (-4.34 %)
(As of 12/17/2017 12:42 PM ET)
Previous Close$4.41
Today's Range$4.30 - $4.73
52-Week Range$1.17 - $6.55
Volume1.97 million shs
Average Volume503,795 shs
Market Capitalization$211.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175

Debt

Debt-to-Equity RatioN/A
Current Ratio24.05%
Quick Ratio24.05%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales3,016.44
Cash FlowN/A
Price / CashN/A
Book Value$3.24 per share
Price / Book1.36

Profitability

Trailing EPS($1.36)
Net Income$-43,880,000.00
Net Margins-82,235.72%
Return on Equity-38.91%
Return on Assets-37.13%

Miscellaneous

Employees76
Outstanding Shares47,880,000

Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) issued its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.20. The biopharmaceutical company had revenue of $0.03 million for the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. Endocyte's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. View Endocyte's Earnings History.

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?

2 brokerages have issued twelve-month price objectives for Endocyte's shares. Their predictions range from $7.00 to $7.00. On average, they expect Endocyte's stock price to reach $7.00 in the next year. View Analyst Ratings for Endocyte.

What are Wall Street analysts saying about Endocyte stock?

Here are some recent quotes from research analysts about Endocyte stock:

  • 1. According to Zacks Investment Research, "Endocyte posted narrower-than-expected loss in the third quarter of 2017. In October 2017, the company accelerated its path to commercialization as it acquired the rights to PSMA-617, being evaluated for the treatment of prostate cancer. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company. Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. So far this year, shares of the company have outperformed the industry." (11/9/2017)
  • 2. Cowen Inc analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:

  • John C. Aplin Ph.D., Independent Chairman of the Board (Age 69)
  • Michael A. Sherman, President, Chief Executive Officer, Director (Age 50)
  • Michael T. Andriole, Chief Financial Officer (Age 44)
  • Philip S. Low Ph.D., Chief Science Officer, Director (Age 67)
  • Michael A. Brinkley, Vice President - Quality (Age 51)
  • Christopher P. Leamon Ph.D., Vice President - Research (Age 49)
  • P. David Mozley M.D., Vice President - Imaging
  • Katherine K. Parker, Vice President of Human Resources (Age 50)
  • Beth A. Taylor, Corporate Controller (Age 49)
  • Cooper Lesley Russell, Director (Age 56)

Who owns Endocyte stock?

Endocyte's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include CAMBRIDGE ISOTOPE LABORATORIES, INC. (7.10%) and Dimensional Fund Advisors LP (0.18%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.

Who sold Endocyte stock? Who is selling Endocyte stock?

Endocyte's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. View Insider Buying and Selling for Endocyte.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of Endocyte stock can currently be purchased for approximately $4.41.

How big of a company is Endocyte?

Endocyte has a market capitalization of $211.16 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-43,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Endocyte employs 76 workers across the globe.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.


MarketBeat Community Rating for Endocyte (ECYT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endocyte (NASDAQ:ECYT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.672.332.33
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$4.50$4.50
Price Target Upside: 92.84% upside92.84% upside135.60% upside135.60% upside

Endocyte (NASDAQ:ECYT) Consensus Price Target History

Price Target History for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ:ECYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2017CowenReiterated RatingHoldHighView Rating Details
10/3/2017WedbushUpgradeNeutral -> Outperform$2.00 -> $7.00HighView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Endocyte (NASDAQ:ECYT) Earnings History and Estimates Chart

Earnings by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.35)($0.55)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Endocyte (NASDAQ:ECYT) Earnings Estimates

2017 EPS Consensus Estimate: ($1.31)
2018 EPS Consensus Estimate: ($0.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171($0.15)($0.15)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 17.68%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte (NASDAQ ECYT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Christopher P LeamonVPSell23,231$5.04$117,084.24View SEC Filing  
11/13/2017Philip S LowInsiderBuy5,600$4.84$27,104.00View SEC Filing  
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endocyte (NASDAQ ECYT) News Headlines

Source:
DateHeadline
Endocyte Added to NASDAQ Biotechnology Index  Endocyte Added to NASDAQ Biotechnology Index  
finance.yahoo.com - December 15 at 9:56 AM
Endocyte, Inc. (ECYT) VP Sells $117,084.24 in StockEndocyte, Inc. (ECYT) VP Sells $117,084.24 in Stock
www.americanbankingnews.com - December 4 at 7:00 PM
Why Endocyte, Inc. Stock Briefly Spiked TodayWhy Endocyte, Inc. Stock Briefly Spiked Today
finance.yahoo.com - December 4 at 5:16 PM
Zacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPSZacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPS
www.americanbankingnews.com - December 3 at 5:36 AM
Endocyte, Inc. (ECYT) Lowered to "Sell" at ValuEngineEndocyte, Inc. (ECYT) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - November 26 at 1:38 PM
ETFs with exposure to Endocyte, Inc. : November 21, 2017ETFs with exposure to Endocyte, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 6:22 PM
Endocytes Stunning Strategic Shift - Seeking AlphaEndocyte's Stunning Strategic Shift - Seeking Alpha
seekingalpha.com - November 14 at 11:35 PM
-$0.16 EPS Expected for Endocyte, Inc. (ECYT) This Quarter-$0.16 EPS Expected for Endocyte, Inc. (ECYT) This Quarter
www.americanbankingnews.com - November 14 at 7:08 PM
Philip S. Low Purchases 5,600 Shares of Endocyte, Inc. (ECYT) StockPhilip S. Low Purchases 5,600 Shares of Endocyte, Inc. (ECYT) Stock
www.americanbankingnews.com - November 14 at 5:02 PM
Endocyte to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)Endocyte to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 10 at 7:54 AM
Endocyte to Present at the Jefferies 2017 London Healthcare ConferenceEndocyte to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 7:54 AM
Wedbush Comments on Endocyte, Inc.s FY2017 Earnings (ECYT)Wedbush Comments on Endocyte, Inc.'s FY2017 Earnings (ECYT)
www.americanbankingnews.com - November 9 at 7:55 AM
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss - NasdaqEndocyte (ECYT) Posts Narrower-than-Expected Q3 Loss - Nasdaq
www.nasdaq.com - November 8 at 5:22 AM
Edited Transcript of ECYT earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of ECYT earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 5:41 AM
Endocyte Reports Third Quarter Financial Results - GlobeNewswire (press release)Endocyte Reports Third Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 12:39 AM
Endocyte, Inc. (ECYT) Announces Quarterly  Earnings Results, Misses Estimates By $0.20 EPSEndocyte, Inc. (ECYT) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS
www.americanbankingnews.com - November 6 at 11:42 PM
Endocyte, Inc. to Host Earnings CallEndocyte, Inc. to Host Earnings Call
finance.yahoo.com - November 6 at 7:37 PM
Endocyte Reports Third Quarter Financial ResultsEndocyte Reports Third Quarter Financial Results
finance.yahoo.com - November 6 at 7:36 PM
Endocyte reports 3Q lossEndocyte reports 3Q loss
finance.yahoo.com - November 6 at 7:36 PM
Comparing Endocyte (ECYT) & Its RivalsComparing Endocyte (ECYT) & Its Rivals
www.americanbankingnews.com - November 6 at 1:18 AM
Will Endocyte (ECYT) Disappoint This Earnings Season?Will Endocyte (ECYT) Disappoint This Earnings Season?
finance.yahoo.com - November 1 at 12:27 AM
Will Endocyte (ECYT) Disappoint This Earnings Season?Will Endocyte (ECYT) Disappoint This Earnings Season?
finance.yahoo.com - October 31 at 7:24 PM
Endocyte Announces Third Quarter 2017 Earnings Conference Call ... - GlobeNewswire (press release)Endocyte Announces Third Quarter 2017 Earnings Conference Call ... - GlobeNewswire (press release)
globenewswire.com - October 30 at 11:54 PM
Endocyte Announces Third Quarter 2017 Earnings Conference CallEndocyte Announces Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 30 at 6:53 PM
Endocyte, Inc. (ECYT) Sees Large Growth in Short InterestEndocyte, Inc. (ECYT) Sees Large Growth in Short Interest
www.americanbankingnews.com - October 26 at 1:20 AM
 Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.35 Per Share Brokerages Anticipate Endocyte, Inc. (ECYT) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - October 25 at 6:40 AM
Why Endocyte Is Rallying TodayWhy Endocyte Is Rallying Today
www.fool.com - October 18 at 1:02 PM
Critical Analysis: Endocyte (ECYT) and Dipexium Pharmaceuticals (PLXP)Critical Analysis: Endocyte (ECYT) and Dipexium Pharmaceuticals (PLXP)
www.americanbankingnews.com - October 16 at 9:08 AM
Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing DealEndocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal
finance.yahoo.com - October 10 at 3:53 PM
BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4
www.nasdaq.com - October 9 at 11:31 PM
Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.35 Per ShareEndocyte, Inc. (ECYT) Expected to Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - October 6 at 8:32 AM
Q3 2017 EPS Estimates for Endocyte, Inc. Reduced by Analyst (ECYT)Q3 2017 EPS Estimates for Endocyte, Inc. Reduced by Analyst (ECYT)
www.americanbankingnews.com - October 6 at 7:42 AM
ETFs with exposure to Endocyte, Inc. : October 3, 2017ETFs with exposure to Endocyte, Inc. : October 3, 2017
finance.yahoo.com - October 4 at 10:44 AM
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira LitigationBiotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
finance.yahoo.com - October 4 at 10:44 AM
Endocytes stock rockets again on heavy volume after license deal for prostate cancer treatment - MarketWatchEndocyte's stock rockets again on heavy volume after license deal for prostate cancer treatment - MarketWatch
www.marketwatch.com - October 3 at 6:04 PM
Why Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today - Investorplace.comWhy Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today - Investorplace.com
investorplace.com - October 3 at 6:04 PM
Endocytes stock rockets again on heavy volume after license deal for prostate cancer treatmentEndocyte's stock rockets again on heavy volume after license deal for prostate cancer treatment
finance.yahoo.com - October 3 at 6:04 PM
Endocyte Inks Deal For Prostate Cancer Candidate, Shares UpEndocyte Inks Deal For Prostate Cancer Candidate, Shares Up
finance.yahoo.com - October 3 at 6:04 PM
Mid-Afternoon Market Update: Tile Shop Drops On Weak Sales Forecast; Endocyte Shares Spike HigherMid-Afternoon Market Update: Tile Shop Drops On Weak Sales Forecast; Endocyte Shares Spike Higher
feeds.benzinga.com - October 3 at 3:27 PM
Why Endocyte, Inc. (ECYT) Stock Is Going Bonkers TodayWhy Endocyte, Inc. (ECYT) Stock Is Going Bonkers Today
investorplace.com - October 3 at 2:16 PM
Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside PossibleEndocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible
feeds.benzinga.com - October 3 at 1:55 PM
Pre-Market Most Active for Oct 3, 2017 : ECYT, BRCD, ERIC, RIGL, GSK, TTS, ZGNX, BAC, GM, TEVA, BABA, MFGP - NasdaqPre-Market Most Active for Oct 3, 2017 : ECYT, BRCD, ERIC, RIGL, GSK, TTS, ZGNX, BAC, GM, TEVA, BABA, MFGP - Nasdaq
www.nasdaq.com - October 3 at 9:56 AM
Endocyte (ECYT) Reports License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in ... - StreetInsider.comEndocyte (ECYT) Reports License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in ... - StreetInsider.com
www.streetinsider.com - October 3 at 9:56 AM
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock - NasdaqOptions Traders Expect Huge Moves in Endocyte (ECYT) Stock - Nasdaq
www.nasdaq.com - October 3 at 9:56 AM
Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate CancerEndocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
finance.yahoo.com - October 3 at 9:56 AM
Closing Bell; Endocyte Spikes: LIVE MARKETS BLOGClosing Bell; Endocyte Spikes: LIVE MARKETS BLOG
finance.yahoo.com - October 3 at 9:56 AM
Todays Research Reports on Stocks to Watch: Endocyte and INSYS TherapeuticsToday's Research Reports on Stocks to Watch: Endocyte and INSYS Therapeutics
finance.yahoo.com - October 3 at 9:56 AM
Options Traders Expect Huge Moves in Endocyte (ECYT) StockOptions Traders Expect Huge Moves in Endocyte (ECYT) Stock
finance.yahoo.com - October 3 at 9:56 AM
Endocyte, Inc. (ECYT) Raised to "Outperform" at WedbushEndocyte, Inc. (ECYT) Raised to "Outperform" at Wedbush
www.americanbankingnews.com - October 3 at 8:41 AM
Mid-Day Market Update: Crude Oil Down 2%; Endocyte Shares Spike HigherMid-Day Market Update: Crude Oil Down 2%; Endocyte Shares Spike Higher
feeds.benzinga.com - October 2 at 12:14 PM

SEC Filings

Endocyte (NASDAQ:ECYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endocyte (NASDAQ ECYT) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.